$3.43
9.26% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US1628281073
Symbol
CKPT
Sector
Industry

Checkpoint Therapeutics, Inc. Stock price

$3.43
+0.79 29.92% 1M
+1.80 110.43% 6M
+1.14 49.78% YTD
+1.55 82.45% 1Y
-36.07 91.32% 3Y
-14.47 80.84% 5Y
-46.57 93.14% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.35 9.26%
ISIN
US1628281073
Symbol
CKPT
Sector
Industry

Key metrics

Market capitalization $167.50m
Enterprise Value $162.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3,256.00
P/S ratio (TTM) P/S ratio 3,350.00
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -72.51%
Revenue (TTM) Revenue $50.00k
EBIT (operating result TTM) EBIT $-37.51m
Free Cash Flow (TTM) Free Cash Flow $-30.76m
Cash position $4.70m
EPS (TTM) EPS $-1.44
P/E forward negative
P/S forward 7,090.42
EV/Sales forward 6,894.58
Short interest 13.37%
Show more

Is Checkpoint Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Checkpoint Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:

Buy
100%

Financial data from Checkpoint Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.05 0.05
71% 71%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.92 9.92
7% 7%
19,840%
- Research and Development Expense 28 28
44% 44%
55,280%
-38 -38
36% 36%
-75,020%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -38 -38
36% 36%
-75,028%
Net Profit -46 -46
14% 14%
-92,940%

In millions USD.

Don't miss a Thing! We will send you all news about Checkpoint Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Checkpoint Therapeutics, Inc. Stock News

Positive
Seeking Alpha
one day ago
Checkpoint Therapeutics, Inc.'s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th is crucial, with potential FDA approval driving significant market growth and revenue projections. Despite competitive pressures and financial risks, cosibelimab's unique mechanism and strong IP posi...
Neutral
GlobeNewsWire
3 days ago
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates.
Neutral
GlobeNewsWire
2 months ago
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024
More Checkpoint Therapeutics, Inc. News

Company Profile

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.

Head office United States
CEO James Oliviero
Employees 23
Founded 2014
Website www.checkpointtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today